DV
Dividend Vision

BEAM — Beam Therapeutics Inc.

Beam Therapeutics Inc. (BEAM)

Total return is 42.7% over the past 6.5 years, 112.3 points behind SPY at 155.0%. Its deepest 1-year drawdown was 38.2%.

BEAM is a single-stock equity holding that represents shares of Beam Therapeutics Inc., a biotechnology company focused on gene editing and therapeutic development. As a stock rather than a diversified fund, it does not pay regular distributions and carries no listed expense ratio, making it distinct from traditional dividend-focused ETFs. This holding appeals primarily to investors seeking exposure to the biotechnology sector and companies involved in precision medicine research, rather than those focused on dividend income.

BEAM key facts

Asset type
Stock
Asset class
Equity
Inception date
02/06/2020
Distribution frequency
None
Last close
$26.75
Market cap
$2,762,945,024
Average volume
1228400.0
Beta
2.209
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.69